Characterization of antibody responses to purified HIV-1 gp120 glycoproteins fused with the molecular adjuvant C3d

Virology

Volumn 340, Issue 2, 2005, Pages 277-284

  Koch, Markus ^a,d   Frazier, James ^a   Sodroski, Joseph ^a,b,c   Wyatt, Richard ^a,e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Glycoprotein; HIV 1; Molecular adjuvant

Indexed keywords

ADJUVANT; ANTIBODY; COMPLEMENT COMPONENT C3D; EPITOPE; GLYCOPROTEIN GP 120; OIL; PHOSPHATE BUFFERED SALINE; PHOSPHOLIPID DERIVATIVE; RIBI; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; WATER;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTES; COMPLEMENT C3D; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ENVELOPE PROTEIN GP120; HIV-1; MICE; MODELS, BIOLOGICAL; RECOMBINANT FUSION PROTEINS; SEQUENCE DELETION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 24944552050     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virol.2005.06.034     Document Type: Article

References (36)

1. G. Alkhatib, C. Combadiere, C.C. Broder, Y. Feng, P.E. Kennedy, P.M. Murphy, and E.A. Berger CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1 Science 272 5270 1996 1955 1958
2. J.R. Baldridge, P. McGowan, J.T. Evans, C. Cluff, S. Mossman, D. Johnson, and D. Persing Taking a toll on human disease: toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents Expert Opin. Biol. Ther. 4 7 2004 1129 1138
3. J.M. Binley, R.W. Sanders, B. Clas, N. Schuelke, A. Master, Y. Guo, F. Kajumo, D.J. Anselma, P.J. Maddon, W.C. Olson, and J.P. Moore A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure J. Virol. 74 2 2000 627 643
4. J.F. Bower, T.D. Green, and T.M. Ross DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1 Virology 328 2 2004 292 300
5. J.F. Bower, X. Yang, J. Sodroski, and T.M. Ross Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d J. Virol. 78 9 2004 4710 4719
6. H. Choe, M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P.D. Ponath, L. Wu, C.R. Mackay, G. LaRosa, W. Newman, N. Gerard, C. Gerard, and J. Sodroski The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates Cell 85 7 1996 1135 1148
7. J.S. Culp, H. Johansen, B. Hellmig, J. Beck, T.J. Matthews, A. Delers, and M. Rosenberg Regulated expression allows high level production and secretion of HIV-1 gp120 envelope glycoprotein in Drosophila Schneider cells Biotechnology 9 2 1991 173 177 (New York)
8. P.W. Dempsey, M.E. Allison, S. Akkaraju, C.C. Goodnow, and D.T. Fearon C3d of complement as a molecular adjuvant: bridging innate and acquired immunity Science 271 5247 1996 348 350
9. H. Deng, R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R.E. Sutton, C.M. Hill, C.B. Davis, S.C. Peiper, T.J. Schall, D.R. Littman, and N.R. Landau Identification of a major co-receptor for primary isolates of HIV-1 Nature 381 6584 1996 661 666
10. B.J. Doranz, J. Rucker, Y. Yi, R.J. Smyth, M. Samson, S.C. Peiper, M. Parmentier, R.G. Collman, and R.W. Doms A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors Cell 85 7 1996 1149 1158
11. + cells is mediated by the chemokine receptor CC-CKR-5 Nature 381 6584 1996 667 673
12. Y. Feng, C.C. Broder, P.E. Kennedy, and E.A. Berger HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor Science 272 5263 1996 872 877
13. N.M. Flynn, D.N. Forthal, C.D. Harro, F.N. Judson, K.H. Mayer, and M.F. Para Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection J. Infect. Dis. 191 5 2005 654 665
14. F. Gao, E.A. Weaver, Z. Lu, Y. Li, H.X. Liao, B. Ma, S.M. Alam, R.M. Scearce, L.L. Sutherland, J.S. Yu, J.M. Decker, G.M. Shaw, D.C. Montefiori, B.T. Korber, B.H. Hahn, and B.F. Haynes Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein J. Virol. 79 2 2005 1154 1163
15. T.D. Green, D.C. Montefiori, and T.M. Ross Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d J. Virol. 77 3 2003 2046 2055
16. C. Grundner, M. Pancera, J.M. Kang, M. Koch, J. Sodroski, and R. Wyatt Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins Virology 330 1 2004 233 248
17. K.M. Haas, F.R. Toapanta, J.A. Oliver, J.C. Poe, J.H. Weis, D.R. Karp, J.F. Bower, T.M. Ross, and T.F. Tedder Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression J. Immunol. 172 10 2004 5833 5837
18. E. Helseth, M. Kowalski, D. Gabuzda, U. Olshevsky, W. Haseltine, and J. Sodroski Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants J. Virol. 64 5 1990 2416 2420
19. M. Ivey-Hoyle, J.S. Culp, M.A. Chaikin, B.D. Hellmig, T.J. Matthews, R.W. Sweet, and M. Rosenberg Envelope glycoproteins from biologically diverse isolates of immunodeficiency viruses have widely different affinities for CD4 Proc. Natl. Acad. Sci. U.S.A. 88 2 1991 512 516
20. F. Liu, I. Mboudjeka, S. Shen, T.H. Chou, S. Wang, T.M. Ross, and S. Lu Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model Vaccine 22 13-14 2004 1764 1772
21. S.I. Miller, R.K. Ernst, and M.W. Bader LPS, TLR4 and infectious disease diversity Nat. Rev., Microbiol. 3 1 2005 36 46
22. H. Molina, W. Wong, T. Kinoshita, C. Brenner, S. Foley, and V.M. Holers Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1 J. Exp. Med. 175 1 1992 121 129
23. M. Pancera, and R. Wyatt Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage Virology 332 1 2005 145 156
24. G. Pantaleo, and R.A. Koup Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know Nat. Med. 10 8 2004 806 810
25. T.M. Ross, Y. Xu, T.D. Green, D.C. Montefiori, and H.L. Robinson Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins AIDS Res. Hum. Retrovir. 17 9 2001 829 835
26. R.W. Sanders, M. Vesanen, N. Schuelke, A. Master, L. Schiffner, R. Kalyanaraman, M. Paluch, B. Berkhout, P.J. Maddon, W.C. Olson, M. Lu, and J.P. Moore Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1 J. Virol. 76 17 2002 8875 8889
27. I.K. Srivastava, L. Stamatatos, E. Kan, M. Vajdy, Y. Lian, S. Hilt, L. Martin, C. Vita, P. Zhu, K.H. Roux, L. Vojtech, D. Montefiori, J. Donnelly, J.B. Ulmer, and S.W. Barnett Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate J. Virol. 77 20 2003 11244 11259
28. I.K. Srivastava, K. VanDorsten, L. Vojtech, S.W. Barnett, and L. Stamatatos Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region J. Virol. 77 4 2003 2310 2320
29. L. Wu, N.P. Gerard, R. Wyatt, H. Choe, C. Parolin, N. Ruffing, A. Borsetti, A.A. Cardoso, E. Desjardin, W. Newman, C. Gerard, and J. Sodroski CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 Nature 384 6605 1996 179 183
30. R. Wyatt, and J. Sodroski The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens Science 280 5371 1998 1884 1888
31. R. Wyatt, E. Desjardin, U. Olshevsky, C. Nixon, J. Binley, V. Olshevsky, and J. Sodroski Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein J. Virol. 71 12 1997 9722 9731
32. R. Wyatt, P.D. Kwong, E. Desjardins, R.W. Sweet, J. Robinson, W.A. Hendrickson, and J.G. Sodroski The antigenic structure of the HIV gp120 envelope glycoprotein Nature 393 6686 1998 705 711
33. X. Yang, M. Farzan, R. Wyatt, and J. Sodroski Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins J. Virol. 74 12 2000 5716 5725
34. X. Yang, L. Florin, M. Farzan, P. Kolchinsky, P.D. Kwong, J. Sodroski, and R. Wyatt Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution J. Virol. 74 10 2000 4746 4754
35. X. Yang, R. Wyatt, and J. Sodroski Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers J. Virol. 75 3 2001 1165 1171
36. X. Yang, J. Lee, E.M. Mahony, P.D. Kwong, R. Wyatt, and J. Sodroski Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin J. Virol. 76 9 2002 4634 4642